Summary: UnitedHealthcare modified its Molecular Pathology/Molecular Diagnostics/Genetic Testing coverage policy for Medicare Advantage members, effective April 14, 2026. Here's what billing teams need to know before claims start hitting this new policy.
UnitedHealthcare — the full official name matters here because this applies specifically to its Medicare Advantage plans — updated this policy governing molecular diagnostics and genetic testing reimbursement. The policy does not publish a specific policy code in its current form. Because no specific CPT, HCPCS, or ICD-10 codes were included in the available policy data, this post addresses the structural change, the billing context you need, and the action items your team should take before the April 14, 2026 effective date.
| Field | Detail |
|---|---|
| Payer | UnitedHealthcare |
| Policy | Molecular Pathology/Molecular Diagnostics/Genetic Testing – Medicare Advantage Medical Policy |
| Policy Code | N/A |
| Change Type | Modified |
| Effective Date | 2026-04-14 |
| Impact Level | High |
| Specialties Affected | Oncology, Pathology, Genetics, Molecular Laboratory, OB/GYN, Neurology, Cardiology |
| Key Action | Pull the full policy from UnitedHealthcare's provider portal and audit your active genetic testing claims against the updated medical necessity criteria before April 14, 2026. |
UnitedHealthcare Genetic Testing Coverage Policy: What the Modification Means in 2026
Genetic testing is one of the highest-scrutiny categories in Medicare Advantage billing. UnitedHealthcare has a long history of tightening medical necessity criteria and prior authorization requirements in this space — and this April 2026 modification continues that pattern.
The UHC molecular pathology/molecular diagnostics coverage policy governs a broad range of tests. That includes hereditary cancer panels, pharmacogenomic testing, somatic tumor profiling, carrier screening, and inherited cardiac and neurological condition testing. Any modification here touches a large volume of claims across multiple specialties.
The real issue with modifications to genetic testing policies is that the changes are rarely obvious. Payers don't always flag when they've tightened a diagnosis requirement or added a prior authorization trigger. A policy that "looks the same" on page one can bury a new exclusion three pages in.
UnitedHealthcare Molecular Diagnostics Coverage Criteria and Medical Necessity Requirements 2026
Whether genetic testing is covered under Medicare Advantage through UnitedHealthcare depends on meeting specific medical necessity criteria. This has always been true, but modifications to this policy typically mean one or more of the following: new required clinical indicators, narrowed diagnosis code pairings, added prior authorization requirements, or reclassification of certain tests as experimental or investigational.
UnitedHealthcare's genetic testing coverage policy for Medicare Advantage evaluates medical necessity based on whether the test result will directly change clinical management. That standard — clinical actionability — is central to how UHC reviews these claims. If the test won't change treatment, UHC considers it not medically necessary regardless of the diagnosis.
Hereditary cancer risk testing, for example, typically requires documented personal or family history criteria. Pharmacogenomic testing faces even more scrutiny. UHC has previously classified many pharmacogenomic panels as experimental for Medicare Advantage members, and this modification may refine that classification further.
Prior authorization requirements in molecular diagnostics are not optional and not administrative formalities. Missing a prior auth on a high-dollar genetic panel will produce a claim denial that is difficult to overturn on appeal. Confirm which tests require prior authorization under the updated policy before your lab or ordering provider submits the request.
UnitedHealthcare Genetic Testing Exclusions and Non-Covered Indications
Across UnitedHealthcare's Medicare Advantage genetic testing coverage policy history, several categories have consistently landed in the not-covered or experimental column. This modification likely touches at least some of these.
Tests commonly classified as experimental or not medically necessary under UHC Medicare Advantage policies include:
| # | Excluded Procedure |
|---|---|
| 1 | Whole genome sequencing and whole exome sequencing ordered without a confirmed rare disease workup |
| 2 | Pharmacogenomic panels used to guide medication selection when no validated clinical utility evidence exists for the specific drug-gene pairing |
| 3 | Expanded carrier screening panels ordered for members outside reproductive age or without a documented clinical indication |
| 4 | Liquid biopsy tests for cancer surveillance when ordered outside of oncology treatment monitoring contexts |
| 5 | Multigene panels that include markers without established clinical validity for the ordered indication |
Because the specific updated exclusion list is not available in the current policy data, pull the full policy document from the UnitedHealthcare provider portal before April 14, 2026. If your practice bills any of these categories, have your compliance officer review the updated exclusion language directly. Do not assume prior coverage status carries forward.
Coverage Indications at a Glance
The policy data provided does not include indication-level criteria with specific CPT or ICD-10 pairings. The table below reflects the general coverage framework UnitedHealthcare applies to this policy category, based on its Medicare Advantage medical policy structure. Treat this as a starting framework — confirm every row against the April 14, 2026 policy version.
| Indication | Status | Notes |
|---|---|---|
| Hereditary breast/ovarian cancer (BRCA1/BRCA2) testing with qualifying family/personal history | Generally Covered | Medical necessity documentation required; prior authorization likely required |
| Lynch syndrome/hereditary colorectal cancer testing with qualifying criteria | Generally Covered | Prior authorization required; specific diagnosis pairings apply |
| Somatic tumor profiling for confirmed malignancy guiding targeted therapy | Generally Covered | Clinical actionability required; prior authorization required for many panels |
| Pharmacogenomic testing for drug metabolism | Frequently Experimental/Not Covered | UHC has classified many PGx panels as experimental under Medicare Advantage; verify current status |
| Whole exome/whole genome sequencing | Frequently Not Covered | Rare exceptions for undiagnosed rare disease with documented workup |
| Expanded carrier screening (reproductive) | Varies by indication | Age and clinical indication scrutiny applies under Medicare Advantage |
| Liquid biopsy for treatment monitoring | Varies by panel and indication | Coverage depends on FDA approval status and clinical indication |
| Prenatal cell-free DNA (NIPT/NIPS) | Covered for high-risk pregnancy | Specific criteria apply; typically not covered as routine screening under Medicare Advantage |
Confirm all coverage determinations against the April 14, 2026 UnitedHealthcare policy document. This table does not substitute for the actual policy text.
UnitedHealthcare Genetic Testing Billing Guidelines and Action Items 2026
Here's what your billing team, lab, and revenue cycle staff need to do before and after April 14, 2026.
| # | Action Item |
|---|---|
| 1 | Pull the updated policy from UHC's provider portal now. Go to UnitedHealthcare's provider portal and download the April 14, 2026 version of the Molecular Pathology/Molecular Diagnostics/Genetic Testing Medicare Advantage Medical Policy. Read it against the prior version. If your team doesn't have access to the prior version for comparison, this is exactly the kind of line-by-line diff that can prevent upstream denials. |
| 2 | Audit your prior authorization workflows for every molecular diagnostic test you order or bill. Prior authorization requirements for genetic testing under UHC Medicare Advantage are specific to test type and indication. If this modification added new prior auth triggers, claims submitted after April 14 without authorization will deny. Run your active test menu against the updated PA requirements before the effective date. |
| 3 | Review your medical necessity documentation templates. UHC's standard for medical necessity in genetic testing is clinical actionability — the test result must change management. Make sure your ordering providers document the clinical question the test will answer and how the result will affect treatment decisions. Generic "rule out" language won't hold up on audit or appeal. |
| 4 | Check your ICD-10 pairings against the updated policy. Genetic testing claims live and die on diagnosis code specificity. If UHC updated the required diagnosis pairings for covered indications, claims with previously-acceptable codes may now deny. Have your coding team map current ICD-10 usage against the updated coverage criteria before April 14, 2026. |
| 5 | Identify any tests now reclassified as experimental. If UHC moved a test your practice regularly orders from "covered with criteria" to "experimental," you need to know that before the claim drops. Review the updated experimental/investigational designation list in the policy and flag any affected tests for your ordering providers and billing team. |
| 6 | Brief your ordering providers on the changes. Claim denials in genetic testing often trace back to orders that don't meet updated medical necessity criteria — not billing errors. Your providers need to know what changed. A 15-minute briefing before April 14 is worth more than 15 appeal letters after. |
| 7 | Set up a denial tracking flag for molecular diagnostics claims post-April 14. If this modification introduced new criteria, you'll see the denial pattern emerge in the first two to four weeks. Flag all molecular pathology and genetic testing denials from UHC Medicare Advantage members for immediate review through May 2026. Early pattern recognition lets you correct workflows before the volume compounds. |
If you're unsure how this modification applies to your specific test mix — especially if you bill complex panels, PGx testing, or somatic tumor profiling — talk to your compliance officer before the April 14, 2026 effective date. The financial exposure on high-dollar genetic panels is too significant to guess.
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Molecular Diagnostics Under UnitedHealthcare's Medicare Advantage Policy
The policy data provided with this change does not include specific CPT, HCPCS, or ICD-10 codes. UnitedHealthcare's Molecular Pathology/Molecular Diagnostics/Genetic Testing policy typically references codes across several ranges, but listing codes not confirmed in the actual policy document would be misleading.
To get the complete, accurate code list for this policy:
- Access the full policy at the UnitedHealthcare provider portal or at app.payerpolicy.org/p/uhc/molecular-pathology-diagnostics-genetic-testing.: https://app.payerpolicy.org/p/uhc/molecular-pathology-diagnostics-genetic-testing
- Look for the policy's code appendix or attached code list — UHC typically publishes covered and non-covered code lists as part of the full policy document
- Cross-reference the code list against your charge master and lab test menu
Molecular pathology billing spans CPT codes in the 81105–81479 range (Tier 1 and Tier 2 molecular pathology codes), proprietary laboratory analyses (PLA codes), and various MAAA codes for multianalyte algorithmic analyses. Whether any or all of these are affected by this specific modification requires review of the actual April 14, 2026 policy document. Do not rely on the prior version's code list without confirming it against the update.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.